Lab-Developed Tests: FDA Gives Extra Time For Input On Oversight Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments submitted thus far largely do not offer detailed suggestions for alternative regulatory regimes, but highlight particular areas in which the agency should take caution.